Matthew J. Brody, Ph.D. is known for his research into the molecular and genetic underpinnings of cardiomyopathy and heart failure. He is an assistant professor in the Departments of Pharmacology and Internal Medicine at the University of Michigan. He received his B.S. in environmental toxicology from the University of California, Davis in 2007 and a Ph.D. in molecular and environmental toxicology from the University of Wisconsin-Madison in 2013. Dr. Brody did postdoctoral training in the Division of Molecular Cardiovascular Biology at Cincinnati Children’s Hospital Medical Center. He joined the faculty at the University of Michigan in 2019. Dr. Brody provides rigorous training in molecular cardiology and cardiac pharmacology to undergraduates, Ph.D. students, and postdoctoral fellows. He teaches at the University of Michigan Medical School in biomedical sciences and in the School of Pharmacy.  

The Brody lab is investigating intracellular signaling mechanisms that underlie the onset and progression of heart disease and cardiovascular protective mechanisms in cardiomyocytes that promote adaptation of the heart and body to stress. The laboratory’s current areas of focus include functions of post-translational lipid modifications in the compartmentalization, sensing, and transduction of pathogenic signals and molecular regulation of cardiomyocyte cytokine receptor signaling and natriuretic peptide secretion. The Brody lab has a broader interest in identifying and elucidating pharmacological strategies to inhibit intracellular signaling pathways that promote cardiac hypertrophy and failure or that promote adaptive signaling circuitry to aide in cardiac resiliency to chronic insult with the goal of reducing or preventing adverse cardiac remodeling that ultimately results in heart failure. Dr. Brody’s research is supported by funding from the National Institutes of Health and the American Heart Association.

Congratulations, Dr. Brody.